MMI's Robotic Microsurgery for Alzheimer's Receives FDA Clinical Trial Approval
MMI received FDA approval for its REMIND study, a clinical trial evaluating a novel, robot-assisted microsurgery for treating Alzheimer's disease. This intervention aims to improve the brain's clearance of amyloid beta and tau proteins, potentially enhancing the natural system for eliminating neurotoxic substances.
Key takeaways
- Medical Microinstruments (MMI), an American-Italian medtech company, has received FDA approval to initiate clinical trials for a novel robotic microsurgery treatment targeting Alzheimer's disease, according to Medtech Magazine
- The FDA granted MMI an Investigational Device Exemption (IDE) for the REMIND study
- The REMIND study will evaluate the feasibility of robot-assisted microsurgery in treating this neurodegenerative condition by enhancing the brain’s clearance of amyloid beta and tau proteins
Related Topics
Want coverage like this for your company?
Local & industry wins build trusted proof, SEO/geo signals and prime national editors.
Verified mention available
Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Want to turn mentions into momentum? Find your best path with the Fit Checker. Verified profiles receive a free consult.